Edition:
United States

Stentys SA (STEN.PA)

STEN.PA on Paris Stock Exchange

2.54EUR
29 Jul 2016
Change (% chg)

€-0.03 (-1.17%)
Prev Close
€2.57
Open
€2.57
Day's High
€2.59
Day's Low
€2.53
Volume
45,929
Avg. Vol
--
52-wk High
--
52-wk Low
--

STEN.PA

Chart for STEN.PA

About

Stentys SA is a French-based company specialized in the development of a new generation of stents for the treatment of acute myocardial infarction or coronary artery disease. It's main product STENTYS Stent, self-expanding coronary bare-metal stent system, is indicated for the treatment of Acute Coronary Syndrome. The Company's... (more)

Overall

Beta: 0.70
Market Cap(Mil.): €45.40
Shares Outstanding(Mil.): 17.87
Dividend: --
Yield (%): --

Financials

  STEN.PA Industry Sector
P/E (TTM): -- 42.33 39.69
EPS (TTM): -0.75 -- --
ROI: -48.95 11.52 14.44
ROE: -55.17 13.49 15.49

BRIEF-Stentys enrolls first patient in Left Main clinical trial

* Stentys enrolls first patient in Left Main clinical trial Source text for Eikon: Further company coverage: (Gdynia Newsroom:)

Jul 19 2016

BRIEF-Stentys reports 41 pct increase in revenues in Q2 2016

* Q2 revenue 2.1 million euros versus 1.5 million euros year ago

Jul 12 2016

BRIEF-Stentys appoints Christophe Lottin as new CEO

* Christophe Lottin, ex second in command at stent company Hexacath, brings 20 years of sales and management experience

Jul 04 2016

BRIEF-Stentys announces CE marking of its longest Xposition stent

* Announces it has received CE Marking for the longest version of its Xposition S Sirolimus-eluting self-apposing stent Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 08 2016

BRIEF- Stentys reports 38% increase in revenues in Q1

* Reports 38 percent increase in revenues in Q1 (1.5 million euro) ($1.69 million) Source text for Eikon: Further company coverage: ($1 = 0.8864 euros) (Gdynia Newsroom)

Apr 13 2016

BRIEF-Stentys' self-apposing coronary stent receives CE marking

* Stentys announces the CE marking of the self-apposing Stent for left main coronary artery disease Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Mar 21 2016

BRIEF-Stentys FY oper loss narrows to 9.5 million euros

* FY operating loss 9.5 million euros ($10.61 million) versus loss of 18.1 million euros year ago

Mar 16 2016

BRIEF-Stentys successfully completes capital increase

* Stentys successfully completes 12.6 million euro ($13.9 million) capital increase

Mar 04 2016

BRIEF-Stentys says results of self-apposing sirolimus-eluting Stent trial published

* Says results of self-apposing sirolimus-eluting Stent trial published in EuroIntervention

Feb 29 2016

BRIEF-Stentys initiates commercialization of self-expanding drug-eluting stent for the below-the-knee indication

* Stentys initiates the commercialization of the first self-expanding drug-eluting stent for the below-the-knee indication

Feb 08 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Sadif Analytics Prime
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Wright Reports
$75.00
Provider : GlobalData
$300.00
Provider : Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.